Compare stocks

Genfit S.A. is a French biopharmaceutical company focused on developing therapeutics and diagnostic solutions for metabolic and liver-related diseases. Known for its work in treating nonalcoholic steatohepatitis (NASH) and other liver diseases, Genfit offers key products including investigational drugs such as elafibranor and diagnostic tests like NIS4 for identifying NASH. Founded in 1999, the company is headquartered in Loos, France. Its strategic positioning lies in addressing unmet medical needs in liver health, supported by a robust research and development pipeline. Genfit's competitive strengths include expertise in nuclear receptor pathways and strategic partnerships with other biopharmaceutical firms.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.